|
White Paper Report - Table of Contents |
| Chapter | Contents | Page | ||
| 1 | Why investors, executives and managers should map technology. | 4 | ||
| 2 | What are the benefits and challenges of technology mapping? | 5 | ||
| 3 |
Why does technology mapping work? Figure 3-1. Where information is published can help analysts |
7 | ||
| 4 |
The technology mapping process. Figure 4-1. Process for Technology Mapping. Figure 4-2. Measurements and Visualizations for segments. Figure 4-3. Summarizes Segments and Categories. Table 4-1. Key Features of each Method for Organizing Data Table 4-2. Color coding in the Company Matrix |
9 | ||
| 5 |
Assessing competitive advantage. (Case Study) Figure 5-1. A strategic view of stent developments… Figure 5-2. Visual Index™ of drug delivery in stents in 2003 Figure 5-3. BSX performance around the publication time period. Companies: Boston Scientific, Guidant, Johnson & Johnson, Medtronic |
19 | ||
| 6 |
Predicting disruptive technologies. (Case Study) Figure 6-1. Patenting activity in catalytic converters. Figure 6-2. Vitality Plot for catalytic converters using IPC codes. Companies: Bowling Green State University, Denso Corp., Ford, H. R. Ross Industries, Honda, Nissan Motor, Northrop Grumman , Paice Corp., Volvo |
23 | ||
| 7 |
Assessing ideas – knowing when to quit! (Case Study) Figure 7-1. Knowing when to quit. A strategic view with a technology stack. |
25 | ||
| 8 |
X-ray of company R&D activity. (Case Study) Figure 8-1. Co-author analysis of a NI glucose R&D program. Fig. 8-2. Patenting activity reveals three major group efforts. Companies: Abbott |
27 | ||
| 9 |
Profile of a power acquisition. Active Screening. (Case Study) Figure 9-1. The Company Matrix is a summary of activity Table 9-1 Rating Scale Table 9-2 Acquisition Opportunities Table Companies: Merck, SIRNA, others |
30 | ||
| 10 | Discussion/Conclusions | 33 | ||
| References | 35 | |||
| Legal Notices | 36 |
|
© Emerging Tech INSIGHTS, Inc. 2011. All Rights Reserved. |
|